PTSDNCT07473505
Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospective Case Series
An observational study of PTSD and Trauma-related Mental Health Symptoms, run by Reset Medical and Wellness Center at 1 site in United States.
Trial summary
This study prospectively evaluates the effects of Integrative Bilateral Cervical Sympathetic Block (BCSB) on trauma-related symptoms in Special Operations Veterans, comparing outcomes in those receiving BCSB alone versus BCSB combined with structured integrative therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PTSD, Trauma-related Mental Health Symptoms, Moral Injury
- What is being tested?
- stellate ganglion block with 0.5% ropivacaine
- Type of treatment
- Surgery or procedure
- How many people
- 75 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Mar 2026to 1 Jul 2027
- How long will I take part?
- 270 Days
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will include adult Special Operations Forces (SOF) veterans with PTSD who meet eligibility criteria who are through the Operator Relief Fund network of care. Individuals with post-traumatic stress disorder (PTSD) are considered a vulnerable population due to potential emotional sensitivity and risk of psychological distress. Because of this, additional safeguards will be used during recruitment and enrollment to prevent coercion, protect autonomy, and support participant well-being. These safeguards include the use of neutral recruitment language, IRB-approved scripts, and clear communication that participation is entirely voluntary. This study will not discriminate based on race, ethnicity, national origin, gender, sexual orientation, religion, marital status, disability, or socioeconomic status. All eligible individuals will be given equal opportunity to participate.
Who may be able to join
- 18 years or older
- PTSD (PCL Score of 33 or greater at baseline screening)
- Willing and able to provide informed consent and complete study procedures
- Fluent in English
- Special Operations Forces Veteran
Who cannot join
- Recent Sympathetic Block: Receipt of any cervical sympathetic block (including stellate ganglion block [SGB], dual sympathetic ganglion block [DSGB], or bilateral SGB/BCSB), whether unilateral or bilateral, within the past 6 months.
- Concurrent interventional clinical trial participation: Currently enrolled in another interventional clinical trial or receiving any experimental treatment targeting PTSD, TBI, or autonomic dysfunction during the study period
- Acute Psychiatric Instability: Currently experiencing acute psychiatric crisis requiring inpatient care, active suicidal or homicidal intent, or untreated mania, psychosis, or severe dissociation
- Medical Contraindications to BCSB: Any known anatomical abnormalities, bleeding disorders, allergy to local anesthetics, pregnancy, or comorbidities that represent a contraindication to receiving a cervical sympathetic block, per the treating physician's judgment.
- Language or communication barriers: Inability to read, speak, or understand English sufficiently to complete informed consent and study assessments
- Low PTSD Symptom Severity at Baseline: PCL-5 Score < 33 at screening, indicating subclinical or minimal PTSD symptoms (Rationale: to ensure measurable clinical benefit and reduce floor effects)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Reset Medical and Wellness Center
Strongsville, Ohio, 44136
Michael Louwers, 8777373810, mlouwers@theresetcenter.com
About this study
Official title: Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospective Case Series.
This study prospectively evaluates the effects of Integrative Bilateral Cervical Sympathetic Block (BCSB) on trauma-related symptoms in Special Operations Veterans, comparing outcomes in those receiving BCSB alone versus BCSB combined with structured integrative therapy. Using standardized FDA-approved dosing, validated symptom measures, and strict safety criteria, the study aims to determine whether this dual-level autonomic intervention improves PTSD-related and TBI-related symptoms, and whether pairing the procedure with therapy enhances durability and overall clinical benefit.
Read the detailed description
This study is a prospective, observational case series designed to evaluate the clinical effects of integrative bilateral cervical sympathetic blocks (BCSB) on trauma-related symptoms in Special Operations Forces (SOF) veterans. The study is conducted through a collaboration between RESET Medical and Wellness Center, a clinical medical practice providing BCSB as part of routine care, and the Operator Relief Fund (ORF), a nonprofit organization that supports SOF veterans seeking treatment for posttraumatic stress and related symptoms.
Participants are adult Special Operations veterans who independently seek BCSB as a clinical intervention. Recruitment occurs through the natural intake flow of ORF. Individuals contacting ORF for support related to trauma symptoms are informed about the opportunity to participate in this research study during onboarding calls conducted by ORF staff. Participation in the study is voluntary and distinct from access to clinical care or ORF support services.
BCSB is a clinical procedure involving targeted sympathetic blockade at the cervical level, administered bilaterally, and is provided at RESET Medical and Wellness Center by licensed clinicians as part of standard medical care. The study does not alter the clinical indication, procedural technique, or clinical decision-making associated with BCSB. All clinical procedures are performed independent of research participation, and individuals may receive BCSB regardless of whether they enroll in the study.
The purpose of this study is to systematically collect longitudinal data on trauma-related psychological symptoms, functional outcomes, and safety indicators following BCSB in a real-world clinical population of SOF veterans. This prospective case series aims to contribute descriptive clinical data regarding symptom trajectories over time following the intervention. The current measures in this study include: PTSD Checklist for DSM-5, Generalized Anxiety Disorder-7, Moral Injury Symptom Scale - Military - Short Form, Adult Hope Scale, and the Neurobehavioral Symptom Inventory Scale.
After providing informed consent, participants complete baseline assessments prior to undergoing BCSB. Follow-up assessments are administered at 7, 30, 60, 90, 180 and 270 days following the procedure to evaluate changes in trauma-related symptoms and related functional domains. At the last survey on 270 days post procedure, they will also be invited to answer questions about how BCSB has effected their mind and bodies. Data collection is conducted remotely using secure electronic survey platforms. The study includes longitudinal follow-up for up to one year following the procedure, as specified in the protocol.
The study collects self-reported psychological measures focused on trauma-related symptoms, as well as additional questionnaires addressing mental health, functional status, and quality-of-life domains, as outlined in the protocol. Clinical procedure data related to BCSB are also collected for research purposes and reporting of adverse events. No experimental manipulation, randomization, or control group is used in this study.
Safety monitoring is conducted through standard clinical care processes at RESET Medical and Wellness Center. Adverse events and serious adverse events are identified through clinical follow-up and participant self-report and are documented and reported in accordance with protocol-defined procedures. Oversight of human subjects protections, including continuing review and adverse event oversight, is provided by an independent institutional review board.
The Operator Relief Fund serves as a recruitment and participant support organization but is not the sponsor of the study and does not provide the clinical intervention. RESET Medical and Wellness Center is responsible for the delivery of the clinical procedure. Research data are collected and managed in compliance with applicable privacy and confidentiality protections, including the use of a study-specific HIPAA authorization.
Participation in the study does not provide financial compensation, nor does it alter the cost or availability of clinical care. Participants may withdraw from the study at any time without penalty or loss of access to clinical services or ORF support. If a participant withdraws, they may be asked to complete an optional survey regarding the reason for withdrawal.
This study is non-randomized, non-blinded, and descriptive in nature. The findings are intended to inform future research and contribute to the understanding of integrative bilateral cervical sympathetic blocks as a clinical intervention for trauma-related symptoms in Special Operations veteran populations.
- Conditions
- PTSD, Trauma-related Mental Health Symptoms, Moral Injury, Anxiety, Traumatic Brain Injury
- Being tested
- stellate ganglion block with 0.5% ropivacaine
- Keywords
- Bilateral Cervical Sympathetic Blocks, Stellate Ganglion Block, PTSD, Combat Veterans, Post Traumatic Stress Disorder, Special Operations Forces Veterans, Trauma Related Symptoms, Anxiety, Moral Injury, Traumatic Brain Injury, Integrative Therapy, Mental Health
- Medical subject headings
- Stress Disorders, Post-Traumatic, Anxiety Disorders, Brain Injuries, Traumatic, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
stellate ganglion block with 0.5% ropivacaineProcedure or surgery
Also called Cervical Sympathetic Block, Dual Level Cervical Sympathetic Block, Dual Level Stellate Ganglion Block, SGB
This study is distinct because it evaluates an integrative, dual-level bilateral cervical sympathetic block (BCSB), a more comprehensive autonomic intervention than the traditional unilateral SGB, specifically in Special Operations Veterans, a uniquely high-trauma, high-TBI population rarely studied. It is also the first to directly compare BCSB alone versus BCSB combined with structured integrative psychological therapy, using a prospective design with validated outcome measures, strict inclusion/exclusion criteria, and standardized FDA-approved dosing. By incorporating TBI-specific symptom tracking and applying IND-level rigor in a specialized trauma-informed clinical setting, this study fills critical gaps left by prior SGB research and offers a clearer understanding of who benefits most and why.
| Study group | Role | What they receive |
|---|---|---|
| Ropivacaine Based BCSB | This cohort consists of combat veterans participating in the RESET study to evaluate the effects of bilateral cervical sympathetic ganglion blocks (BCSB) on post-traumatic stress symptoms and suicide risk. Participants receive one procedures as a clinical intervention. Some participants may decided to access additional therapies, making BCSB an integrative model. Receives: Procedure: stellate ganglion block with 0.5% ropivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
PTSD Checklist for the DSM-5
In a military context, the PTSD Checklist for the DSM-5 (PCL-5) is one of the most commonly used psychological questionnaires. Derived from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the PCL-5 contains 20 self-report items assessing the degree to which individuals have been bothered by PTSD symptoms. Items are rated on a Likert scale ranging from 0 to 4. Individuals who score 33 or higher on the PCL-5 meet the cutoff commonly used to indicate PTSD. The PCL-5 has demonstrated internal consistency and validity in civilian populations, as well as in a study of service members (N = 12) (Wortmann et al., 2016).
Measured: From baseline to 7, 30, 60, 90, 180 and 270 days post BCSB procedure.
Secondary outcomes (4)
General Anxiety Disorder - 7
Often used by the Veterans Health Administration, the Generalized Anxiety Disorder-7 (GAD-7) is a brief self-report measure designed to assess the severity of generalized anxiety disorder. The GAD-7 consists of seven items assessing anxiety symptoms and their severity over the past two weeks. The GAD-7 has been shown to be internally consistent and valid for use in both civilian and veteran populations (Ahmadi et al., 2023).
Measured: From baseline to 7, 30, 60, 90, 180 and 270 days post BCSB procedure.
Adult Hope Scale
Created in 1991, the Adult Hope Scale (AHS) is based on the theory that hope plays a crucial role in an individual's overall well-being. The AHS contains 12 items that assess an individual's motivation to achieve goals as well as their perceived ability to develop strategies to meet those goals. The AHS is a well-established measure and has demonstrated reliability (Labrosciano et al., 2025).
Measured: From baseline to 7, 30, 60, 90, 180 and 270 days post BCSB procedure.
Moral Injury Symptom Scale - Military Short Form
Developed by Koenig et al. (2018), the Moral Injury Symptom Scale - Military Short Form (MISS-M-SF) is a shortened military-specific version of the original Moral Injury Symptom Scale designed for use in active-duty and veteran populations. Moral injury is a subset of trauma related to moral, spiritual, and religious distress arising from events involving ethical conflict. Such events may include witnessing or causing violence, dehumanizing others, or observing leaders or peers violate moral beliefs. A common example of moral injury is guilt related to surviving an event in which others were injured or killed. The short-form version was created using the highest factor-loading items from the original scale. These 10 items assess domains including betrayal of leaders, guilt, shame, trust, meaning, forgiveness, failure, and religious struggles. The MISS-M-SF has demonstrated high reliability and validity (Koenig et al., 2018).
Measured: From baseline to 7, 30, 60, 90, 180 and 270 days post BCSB procedure.
Neurobehavioral Symptom Inventory
There is a 28% chance that a military service member will experience TBI (Mulvaney et al., 2024). For the majority (80%) of these troops, their TBI is blast exposure related, often causing cerebral edema and vasospasm (Lindberg et al., 2022). TBI is also associated with chronic traumatic encephalopathy and Alzheimer's disease over time. For individuals with TBI, there is a 43.9% likelihood of also experiencing PTSD. Practitioners began to notice that patients who had PTSD/TBI were reporting decreased headaches and brain fog after BCSB (Mulvaney et al., 2024). The NSI is the scaled used at the Department of Veterans Affairs (VA) if they have previously screened positive for TBI (Ashendorf, 2019).
Measured: From baseline to 7, 30, 60, 90, 180 and 270 days post BCSB procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start20 Mar 2026 (estimated)
- Primary completion24 Feb 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for PTSDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
- Target duration
- 270 Days
Sponsor and investigators
- Lead sponsor
- Reset Medical and Wellness Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael Louwers, Reset Medical and Wellness Center
- Investigators
- Michael Louwers, MD, Principal investigator, Reset Medical and Wellness Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07473505
- Sponsor's protocol ID
- Pro00091559
- Status last verified
- Mar 2026
- First submitted
- 11 Mar 2026
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study team has elected not to share individual participant data, including deidentified datasets. This decision is based on ethical and methodological considerations specific to the study population and design. Participants are Special Operations Forces veterans, a population for whom concerns about privacy, stigma, and downstream use of sensitive mental health data may negatively affect willingness to participate. Additionally, given the observational case series design, small sample size, and context-dependent clinical variables, secondary analyses by external parties could result in misinterpretation or inappropriate conclusions that do not reflect the study's intent or limitations. Aggregate results and summary-level findings will be reported publicly through ClinicalTrials.gov and peer-reviewed publications to support transparency while prioritizing participant trust and data integrity.
Publications
Wortmann JH, Jordan AH, Weathers FW, Resick PA, Dondanville KA, Hall-Clark B, Foa EB, Young-McCaughan S, Yarvis JS, Hembree EA, Mintz J, Peterson AL, Litz BT. Psychometric analysis of the PTSD Checklist-5 (PCL-5) among treatment-seeking military service members. Psychol Assess. 2016 Nov;28(11):1392-1403. doi: 10.1037/pas0000260. Epub 2016 Jan 11.
PubMed 26751087Lindberg MA, Moy Martin EM, Marion DW. Military Traumatic Brain Injury: The History, Impact, and Future. J Neurotrauma. 2022 Sep;39(17-18):1133-1145. doi: 10.1089/neu.2022.0103. Epub 2022 Jun 3.
PubMed 35451333Labrosciano K, Dorrian J, Lowies B, Russell R, Lushington K. Adult Hope Scale: validation in older adults. Aust J Psychol. 2025 Jul 30;77(1):2532077. doi: 10.1080/00049530.2025.2532077. eCollection 2025.
PubMed 40746328Koenig HG, Ames D, Youssef NA, Oliver JP, Volk F, Teng EJ, Haynes K, Erickson ZD, Arnold I, O'Garo K, Pearce M. Screening for Moral Injury: The Moral Injury Symptom Scale - Military Version Short Form. Mil Med. 2018 Nov 1;183(11-12):e659-e665. doi: 10.1093/milmed/usy017.
PubMed 29590380Ashendorf L. Neurobehavioral symptom validity in U.S. Department of Veterans Affairs (VA) mild traumatic brain injury evaluations. J Clin Exp Neuropsychol. 2019 May;41(4):432-441. doi: 10.1080/13803395.2019.1567693. Epub 2019 Feb 4.
PubMed 30712457Ahmadi A, Ponder WN, Carbajal J, Schuman DL, Whitworth J, Yockey RA, Galusha JM. Validation of the PCL-5, PHQ-9, and GAD-7 in a Sample of Veterans. J Occup Environ Med. 2023 Aug 1;65(8):643-654. doi: 10.1097/JOM.0000000000002898. Epub 2023 Jun 1.
PubMed 37264532Mulvaney SW, Lynch JH, Mahadevan S, Dineen KJ, Rae Olmsted KL. The Effect of Bilateral, Two-Level Cervical Sympathetic Chain Blocks on Specific Symptom Clusters for Traumatic Brain Injury, Independent of Concomitant PTSD Symptoms. Brain Sci. 2024 Nov 27;14(12):1193. doi: 10.3390/brainsci14121193.
PubMed 39766392